SCHEMBL334975

SCHEMBL334975

CCOC(=O)Cc1[nH]c2ccc(O)c(-c3ccc4c(c3)OCO4)c2c1C(=O)OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.48
KDM4E B2RXH2 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
TP53 P04637 3/20 0.48
PRKCI P41743 1/20 0.47
PRKCZ Q05513 1/20 0.47
SIRT2 Q8IXJ6 2/20 0.46
SIRT1 Q96EB6 2/20 0.46
SIRT3 Q9NTG7 1/20 0.46
MAPT P10636 7/20 0.43
MAPK1 P28482 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
JAK2 O60674 1/20 0.43
JAK3 P52333 1/20 0.43
ALDH1A1 P00352 5/20 0.42
HPGD P15428 5/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
TSHR P16473 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5506452 0.81 ALDH1A1 (0.48) HSD17B10KDM4ESMN1; SMN2MAPTNPC1
SCHEMBL1414526 0.80 GAA (0.35) HSD17B10KDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL5504449 0.79 ALOX5 (0.39) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL5505103 0.79 LMNA (0.39) HSD17B10KDM4ETP53SIRT2SIRT1
SCHEMBL5501345 0.78 POLB (0.42) HSD17B10KDM4ETP53MAPTNPC1
SCHEMBL5266671 0.78 POLB (0.41) HSD17B10KDM4ESMN1; SMN2TP53MAPT
SCHEMBL5512279 0.77 TLR9 (0.38) SMN1; SMN2TP53MAPTALDH1A1GAA
SCHEMBL1414527 0.76 GAA (0.35) HSD17B10KDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL5507785 0.74 ALOX5 (0.42) HSD17B10KDM4ESMN1; SMN2TP53MAPT
SCHEMBL22117121 0.72 PRKCI (0.56) HSD17B10KDM4ESMN1; SMN2TP53PRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097623-B2 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics BIOLIPOX AB (SE) 2012-01-17 US disclosed
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG HSD17B10 3244/4885KDM4E 1104/4885SMN1; SMN2 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.